The CFO's complete licensing deal due diligence checklist

Every deal that blows up had warning signs.

Not always in the headlines. Not always in the press release. Usually in the documents that nobody read carefully enough, the questions that were not asked at the right moment, and the criteria for walking away that were never written down before the pressure to close began.

I have spent more than two decades advising on licensing transactions in pharma, biotech, and MedTech. The deals that failed, and some of the failure modes have been dramatic, almost always had one thing in common: the finance function was not sufficiently embedded in the diligence process at the stage when it still mattered.

This article is the practical output of that experience. It is the checklist I would want in the hands of every CFO, VP Finance, and deal team accountant before they sign anything.

Why this exists

Why checklists matter in licensing deals

Licensing deals are not standard commercial transactions. They are complex, multi-layered arrangements that combine intellectual property, regulatory contingencies, commercial projections, performance obligations, and balance sheet consequences that can play out over a decade or more.

The IFRS accounting treatment is not cosmetic. Revenue recognition under IFRS 15, the capitalisation of associated costs under IAS 38, the classification of embedded derivatives, the accounting for contingent consideration under IFRS 3, and the impairment testing requirements under IAS 36 are all live from the moment the agreement is signed. The choices made at the deal structuring stage become accounting constraints that finance teams will manage for years.

A checklist forces discipline. It creates a record of what was reviewed, what questions were asked, and, critically, what answers were received. When a deal later encounters difficulty, that documentation is not merely useful; it is essential.

Domain 1 · Points 1–9

Deal structure and IFRS classification

1. What is the legal form of the arrangement?

Licence, collaboration, co-development, joint venture, distribution agreement — the legal label does not determine the accounting. Establish the substance of what is being transferred or shared.

2. Does the licence transfer at a point in time or over time?

Under IFRS 15, an intellectual property licence is either functional (point in time) or symbolic (over time). The distinction determines when and how revenue is recognised. This is not a minor technical point — it can shift hundreds of millions of euros in revenue across reporting periods.

3. Are there bundled performance obligations?

Many licensing deals bundle the licence with development services, manufacturing access, promotional support, or data rights. Each obligation must be identified and assessed for whether it is distinct. Bundling that the commercial team treats as a single deal may be multiple performance obligations under IFRS 15.

4. What is the standalone selling price of each identified performance obligation?

Where observable prices do not exist, an estimate must be made and documented. The method used — adjusted market assessment, expected cost plus margin, or residual approach — will be challenged by auditors. Have the methodology and assumptions been approved by finance before the deal closes?

5. Does the arrangement include variable consideration?

Milestones, royalties, earn-outs, tiered payments, and minimum guarantees all constitute variable consideration. Under IFRS 15, variable consideration is included in the transaction price only to the extent that a significant revenue reversal is not probable. The constraint must be applied rigorously, not optimistically.

6. Are there any embedded leases under IFRS 16?

Licensing arrangements that include exclusive access to manufacturing capacity, specific equipment, or dedicated production lines may contain an embedded lease. If so, the lessee must recognise a right-of-use asset and a lease liability at commencement.

7. Does the arrangement create a joint arrangement under IFRS 11?

Where two parties share control of a deal structure, the arrangement may be a joint operation or a joint venture, each with materially different accounting consequences. Establish control and shared decision-making provisions explicitly.

8. What consolidation implications arise under IFRS 10?

Where special purpose entities, holding structures, or intermediate vehicles are used, assess whether any entity is controlled within the meaning of IFRS 10. Control can arise through contractual rights, not merely through equity ownership.

9. Has the tax treatment been aligned with the accounting treatment?

Transfer pricing, withholding tax on royalties, VAT or other indirect tax on milestone payments — the accounting and tax positions must be determined together, not sequentially.

Domain 2 · Points 10–18

Financial terms and cash flow exposure

10. What is the total cash commitment over the life of the deal?

Aggregate the upfront payment, committed milestone payments, minimum royalty guarantees, earn-out obligations, and any regulatory milestone clawback provisions. The headline deal value is rarely the economic exposure.

11. Are there minimum royalty guarantees?

If so, model the cash shortfall scenario explicitly. What is the guaranteed minimum payment? Over how many years? What sales volume is required to cover the guarantee? What is the probability-weighted shortfall? Articles 1 and 2 in this series documented in detail how minimum guarantees destroy companies that assumed their sales projections were conservative.

12. What milestone payment schedule applies, and what triggers each payment?

Map every milestone to its trigger event, the expected timing, the cash amount, and the probability assessment. Distinguish between technical milestones (within the company's control) and regulatory milestones (outside it).

13. Are there clawback provisions on any milestone payments?

If commercial milestones are not achieved within a specified window after regulatory approval, does any previously paid milestone become repayable? Model the worst-case scenario.

14. What are the earn-out provisions, and over what period do they apply?

Multi-year earn-out obligations create ongoing performance measurement requirements. Ensure the earn-out formula is unambiguous and that the data required to calculate it will be accessible and auditable.

15. Has a 24-month cash flow projection been prepared?

Month-by-month, reflecting all contractual payment obligations, projected royalty inflows, and milestone receipts. Has the projection been stress-tested against a scenario in which sales are 50 per cent below projection?

16. What are the working capital implications of the deal?

Large upfront payments may require financing. Royalty receivables on long credit terms may create cash flow gaps. If the company is a licensee, is working capital adequate to sustain the minimum guarantee obligations through the product ramp-up period?

17. Are there currency mismatches between payment obligations and revenue streams?

Milestone obligations denominated in US dollars against euro-denominated revenue, for example, create foreign exchange exposure that must be identified and hedged or disclosed.

18. Has the deal been modelled under a scenario in which regulatory approval is delayed by 12 months? By 24 months?

Development timelines consistently overrun. The cash flow consequences of delay must be modelled before signature, not discovered after.

Domain 3 · Points 19–28

Document review — red flags in every deal document

19. Has finance reviewed the full contract, not the term sheet or the commercial summary?

Term sheets are optimistic summaries. Contracts contain the definitions, conditions, carve-outs, and payment mechanics that determine the actual economic exposure. Finance must read the full agreement.

20. Are payment definitions consistent throughout the contract?

"Net sales," "eligible sales," "qualifying revenue," and "applicable receipts" are not interchangeable. If royalties are calculated on "net sales," ensure the definition of net sales deductions — chargebacks, rebates, government pricing adjustments — has been reviewed and modelled.

21. Does the milestone definition include a subjectivity clause?

Some contracts define milestone achievement as subject to the mutual agreement of the parties, or to the determination of a scientific committee. Where milestone payments are contingent on a party's own assessment, the accounting and commercial risk is materially different from an objective trigger.

22. Are there audit rights over the royalty calculation?

If the company is a licensor receiving royalties calculated by the licensee, does the agreement include the right to audit the licensee's sales records? What is the frequency, notice period, and dispute resolution mechanism?

23. Does the termination clause allow termination for convenience?

If the licensee can terminate without cause on 90 days' notice, the deal is not the 10-year arrangement it appears to be. Revenue recognition projections and capitalised cost amortisation periods must reflect the realistic term of the arrangement, not its maximum permitted duration.

24. Are there change of control provisions?

If either party is acquired, does the deal terminate automatically, or does the acquirer inherit the obligations? This is directly relevant to deal valuation and to the accounting for any contingent consideration under IFRS 3.

25. What representations and warranties survive closing, and for how long?

Identify any financial representations made by either party that could give rise to indemnification claims post-closing. These are contingent liabilities that must be assessed and, where material, disclosed under IAS 37.

26. Is there a most-favoured-nation clause?

If the licensor grants a third party more favourable terms, is the company entitled to equivalent terms? Conversely, if the company is the licensor, could a most-favoured-nation obligation to this licensee be triggered by a future deal on better terms?

27. Are there sublicensing rights, and if so, what revenue-sharing obligations apply?

Sublicensing arrangements introduce an additional layer of performance obligation analysis. If the company can sublicense and must share sublicensing income with the original licensor, the accounting for that income must be carefully structured.

28. Have all side letters and ancillary agreements been reviewed?

Commercial teams sometimes execute side letters that modify the main agreement without informing finance. These must be identified and included in the accounting analysis. A representation should be obtained from the commercial team that no undisclosed side arrangements exist.

Domain 4 · Points 29–36

Questions to ask at each negotiation stage

At term sheet stage

29. Has finance been invited to the term sheet discussion?

If not, escalate. The headline economics — upfront payment, milestone structure, royalty rate, minimum guarantee — are set at term sheet stage and are very rarely improved in subsequent negotiation. Finance's ability to influence the deal structure is at its highest before the term sheet is agreed.

30. What is the licensor's revenue recognition model for this transaction, and does it create a conflict with ours?

If the licensor is recognising the upfront payment immediately and the licensee is amortising the same payment over the licence term, both treatments may be acceptable under IFRS 15, but their financial statement implications are very different. Understand both sides of the accounting equation.

At heads of terms or letter of intent stage

31. Has the variable consideration constraint been applied to the milestone schedule?

Before the milestone payment schedule is locked, finance should confirm which milestones are sufficiently probable to be included in the transaction price, and which are constrained. Milestones that are excluded from the transaction price at inception will require reassessment at each reporting date.

32. Have the performance obligation boundaries been documented and agreed internally?

Finance and the commercial team must agree on what constitutes each performance obligation before the agreement is signed. Disagreements about whether a supply obligation is distinct from the licence are far more difficult to resolve post-signature.

At contract drafting stage

33. Are the payment mechanics consistent with the accounting treatment?

Royalty payment timing — quarterly in arrears, for example — creates receivables that must be recognised before cash is received. The payment schedule in the contract must be visible to the finance team so that the accrual and receivable schedule can be maintained accurately.

34. Has the impairment trigger been assessed for any associated intangible asset?

Where upfront licence payments are capitalised as intangible assets under IAS 38, what is the impairment indicator? Regulatory failure, significant commercial underperformance, or the loss of key personnel may all constitute impairment triggers. These should be defined before signature so that impairment monitoring is systematic rather than reactive.

In the final negotiation phase

35. What concessions are being made in the final 72 hours of negotiation, and do any of them have accounting consequences?

It is common for commercial concessions — additional milestone payments, extended royalty terms, modified minimum guarantee provisions — to be agreed at the eleventh hour of a negotiation. Finance must be notified of any last-minute changes before the agreement is executed.

36. Has legal confirmed that the executed agreement matches the version that finance reviewed?

This sounds elementary. It is not always done. Where amendments are made in final execution copies, finance must confirm it has reviewed the final executed version, not the penultimate draft.

Domain 5 · Points 37–43

Criteria for walking away

Walking away from a deal is one of the most professionally difficult decisions a CFO will make. The commercial team has invested months of effort. The board is expecting a transaction. The partner has already been announced to the market in some cases. The pressure to close can be overwhelming.

37. Define your minimum acceptable milestone probability threshold.

If fewer than 70 per cent of the milestone payments — by value — meet the probability threshold for inclusion in the transaction price, the deal economics do not support the announced headline. That is a walk-away criterion.

38. Define your maximum acceptable minimum royalty guarantee exposure.

If the minimum royalty guarantee exceeds 18 months of the company's projected cash reserves in a downside scenario, the guarantee represents an existential rather than a commercial risk. That is a walk-away criterion.

39. Define your maximum total contingent obligation as a multiple of unrestricted cash.

Aggregate all contingent obligations — minimum guarantees, milestone payments triggered by events outside the company's control, clawback provisions. If the total exceeds three times unrestricted cash, the company cannot absorb a simultaneous adverse realisation of those obligations. That is a walk-away criterion.

40. Define your accounting non-negotiables.

There are deal structures that are commercially attractive but accounting problematic. If the structure requires the recognition of revenue that cannot be supported under IFRS 15, or the capitalisation of costs that do not meet the IAS 38 recognition criteria, or the consolidation of an entity that creates an unacceptable risk profile — those are walk-away criteria. The accounting cannot be bent to fit the deal.

41. Define your disclosure threshold.

If the transaction would require disclosure of contingent liabilities that, in the CFO's assessment, would damage the company's market position, its credit relationships, or its regulatory standing — that is a walk-away consideration, not merely a disclosure management exercise.

42. Define the asymmetry threshold.

If the partner's obligations under the arrangement are substantially less onerous than the company's — if the partner can exit easily but the company cannot, if the partner's milestone obligations are soft while the company's minimum guarantee obligations are hard — the arrangement is structurally asymmetric. Document the asymmetry and require it to be corrected before signature.

43. Define the decision authority.

Who in the organisation has the authority to walk away? Is it the CFO alone, the CFO and CEO jointly, or the board? The answer should be agreed before the pressure to close begins, and the CFO's authority to halt a transaction pending resolution of accounting concerns must be explicit.

When you have to say it

How to explain the decision to walk away

When a CFO recommends walking away from a deal, the explanation must be precise, evidence-based, and framed in terms that are credible to a board that may not have the same level of accounting fluency.

The structure that works best: state the specific criterion that has not been met. Do not generalise. "The minimum royalty guarantee creates a cash exposure of €72 million over five years against unrestricted cash of €38 million, which exceeds the board-approved risk threshold" is a precise statement that can be evaluated. "The deal economics are uncertain" is not.

Show the stress-tested model. The 24-month cash flow projection under the downside scenario is not an opinion — it is arithmetic.

Distinguish between accounting concerns and commercial concerns. An accounting non-negotiable is different from a commercial preference. Be explicit about which category each concern falls into, because the responses available to the board are different in each case.

Quantify the cost of proceeding versus the cost of walking away. Walking away from a signed deal has costs — reputational, relational, and financial. Those costs should be quantified and set against the costs of proceeding with a structurally deficient arrangement.

Document the recommendation and the reasons in writing. The CFO's recommendation to walk away should be in writing, addressed to the board, before the final decision is made. This protects the CFO, creates a record of the governance process, and ensures the board has made a fully informed decision.

Domain 6 · Points 44–47

Post-signature monitoring

44. Is there a formal quarterly review process for each variable consideration element?

Under IFRS 15, variable consideration must be reassessed at each reporting date. The probability assessments made at inception are not permanent. A formal review process, with documented outputs, is not optional — it is an accounting requirement.

45. Has an impairment monitoring schedule been established for all associated intangible assets?

Each capitalised licence payment, each capitalised milestone payment, and each capitalised development cost must be subject to regular impairment assessment. The triggers identified at signature should be built into the monitoring schedule.

46. Are the financial statement disclosures for this arrangement reviewed by a senior member of the finance team at each reporting period?

Disclosure quality deteriorates over time when arrangements become routine. The disclosures for a material licensing arrangement — the performance obligations, the transaction price allocation, the variable consideration constraints, the contingent liabilities — must be reviewed with the same rigour at year five as at year one.

47. Is there a trigger for escalation if the arrangement is performing materially below the original projections?

If actual royalty income falls more than 20 per cent below the original projection, or if a milestone payment is delayed by more than six months, there should be an automatic escalation to the CFO. Performance deterioration below trigger thresholds is one of the most common precursors to accounting crisis in licensing arrangements.

The point

The conversations that do not happen until the deal blows up

The questions in this checklist are not exotic or technically obscure. Most of them are the questions that finance teams retrospectively confirm were not asked in the immediate aftermath of a deal that went wrong.

The minimum royalty guarantee that destroyed a company's cash position was in the term sheet. The clawback provision that triggered a restatement was in a side letter that commercial closed without informing finance. The milestone that was recognised as revenue before it was probable was approved by an external auditor who did not push back hard enough.

That is the standard to which a CFO's diligence should be held. And it is the standard that this checklist is designed to meet.

What comes next

Series continues

This is Article 3 in the MIO Consult pharma licensing series. Article 1 examined the balance sheet consequences of a €200 million deal that triggered a €95 million write-down. Article 2 analysed the hidden liabilities — minimum royalty guarantees, clawback provisions, and working capital mismatches — that destroyed a company's cash position after a headline transaction.

The series continues with Article 4: "When the auditors miss it: how licensing deal accounting errors reach the financial statements."

Subscribe to be notified →